Analyst Consensus ?
ConsensusBuy12 ratings
Bullish975.0%
Neutral216.7%
Bearish18.3%
Solventum Corporation · SOLV · FY2024 Q4 · Calendar Q1 2025
Solventum Q4: Growth improved, but execution risks remain
The supplied analysis supports a measured version of the growth hypothesis for Solventum: improving volume, new products, autonomous coding, and transformation initiatives provide potential growth drivers, but the evidence is balanced by execution, divestiture, SKU, FX, and tariff risks.
Reported After market closeNYSEHealthcare
$14.54B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $1.31
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $2.05B
Revenue surprise
—
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-4.4%
Event window
SPY move
+1.6%
Same window
Abnormal move
-6.0%
Stock minus SPY
Volume
2.1×
Versus trailing sessions
Subsequent drift
-6.3%
Up to 20 sessions
SOLVSPY benchmark
Ask FN2 about SOLV FY2024 Q4
Transcript, numbers and history already loaded
What drove SOLV's -4.4% move after FY2024 Q4 earnings?What changed in SOLV's guidance and outlook in FY2024 Q4?Give me the bull and bear case for SOLV after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current analysis highlights 2.3% Q4 organic sales growth, three consecutive quarters of volume improvement, a planned Purification & Filtration divestiture to Thermo Fisher, 2025 financial guidance, and expanded transformation initiatives including autonomous coding and a Brazil plant.
Guidance delta
Management supplied 2025 guidance of 1%-2% organic growth, 20%-21% operating margin, EPS of $5.45-$5.65, and free cash flow of $450-$550 million.
Key takeaways
- Q4 organic sales grew 2.3%, with volume improving for a third consecutive quarter.
- Management emphasized commercial excellence, product development, and strategic M&A.
- The Purification & Filtration divestiture is intended to be EPS-neutral and support debt reduction.
- AI-driven autonomous coding, ERP implementation, and a new Brazil plant are key execution areas.
Management priorities
- Advance the three-phase transformation and commercial excellence initiatives.
- Complete ERP implementations and construction of the Brazil plant.
- Continue SKU rationalization and expand autonomous coding and data-integrity offerings.
- Pursue tuck-in acquisitions beginning in early 2026 and reduce debt.
Follow SOLV with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$85.41Current
$43Low
$85.1Average
$113High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 25, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Sep 14, 2026 |
| Wedbush | Outperform | Outperform | Maintain | Aug 6, 2026 |
| UBS | Buy | Buy | Maintain | Aug 6, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 6, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Aug 6, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | May 6, 2026 |
| Mizuho | Outperform | Neutral | Upgrade | Jan 20, 2026 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Jul 15, 2025 |
| Argus Research | Buy | Hold | Upgrade | Jul 1, 2025 |
| Goldman Sachs | Sell | Sell | Maintain | Mar 3, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Feb 26, 2025 |
Named analyst price targets
Upside is calculated against the persisted current price $85.41. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Stifel Nicolaus | Analyst unavailable | $100 | $84.82 | +17.1% | Aug 6, 2026 |
| UBS | Patrick Wood | $101 | $87.47 | +18.3% | Aug 6, 2026 |
| Mizuho Securities | Analyst unavailable | $113 | $87.47 | +32.3% | Aug 6, 2026 |
| KeyBanc | Analyst unavailable | $102 | $87.47 | +19.4% | Aug 6, 2026 |
| BTIG | Ryan Zimmerman | $95 | $87.47 | +11.2% | Aug 6, 2026 |
| UBS | Analyst unavailable | $95 | $80.47 | +11.2% | Jul 28, 2026 |
| BTIG | Analyst unavailable | $91 | $76.7 | +6.5% | Jul 13, 2026 |
| BMO Capital | Analyst unavailable | $81 | $75.18 | -5.2% | Jul 8, 2026 |
| Jefferies | Analyst unavailable | $43 | $74.95 | -49.7% | Jun 1, 2026 |
| Wedbush | Michael Piccolo | $94 | $74.42 | +10.1% | May 15, 2026 |
| UBS | Kevin Caliendo | $78 | $71.36 | -8.7% | May 6, 2026 |
| Stifel Nicolaus | Analyst unavailable | $90 | $69.04 | +5.4% | May 6, 2026 |
| KeyBanc | Brett Fishbin | $93 | $69.04 | +8.9% | May 6, 2026 |
| KeyBanc | Brett Fishbin | $92 | $68.52 | +7.7% | Apr 27, 2026 |
| Piper Sandler | Analyst unavailable | $92 | $68.88 | +7.7% | Apr 17, 2026 |
| KeyBanc | Brett Fishbin | $97 | $78.91 | +13.6% | Jan 26, 2026 |
| Mizuho Securities | Analyst unavailable | $100 | $79.48 | +17.1% | Jan 20, 2026 |
| Stifel Nicolaus | Analyst unavailable | $105 | $83.16 | +22.9% | Jan 7, 2026 |
| BTIG | Ryan Zimmerman | $100 | $85.56 | +17.1% | Dec 2, 2025 |
| UBS | Kevin Caliendo | $77 | $73 | -9.8% | Oct 1, 2025 |
| Morgan Stanley | Patrick Wood | $103 | $73.68 | +20.6% | Jul 15, 2025 |
| Mizuho Securities | Analyst unavailable | $82 | $80.16 | -4.0% | Mar 3, 2025 |
| Wells Fargo | Analyst unavailable | $75 | $79.75 | -12.2% | Feb 28, 2025 |
| Mizuho Securities | Steven Valiquette | $70 | $72.28 | -18.0% | Dec 3, 2024 |
| Stifel Nicolaus | Rick Wise | $82 | $66.29 | -4.0% | Oct 7, 2024 |
| Piper Sandler | Jason Bednar | $71 | $67.74 | -16.9% | Oct 7, 2024 |
| Morgan Stanley | Patrick Wood | $55 | $49 | -35.6% | Jul 15, 2024 |
| Goldman Sachs | David Roman | $54 | $59.72 | -36.8% | May 30, 2024 |
| Morgan Stanley | Patrick Wood | $70 | $65.52 | -18.0% | Apr 9, 2024 |
| Wells Fargo | Vik Chopra | $69 | $70.06 | -19.2% | Apr 8, 2024 |
Track every rating change on SOLV the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationSolventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes.…
Historical context
All SOLV earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
| MOH Molina Healthcare, Inc. | FY2026 Q3 · Calendar Q4 2026 | +12.7% | +0.8% | Molina reaffirms 2026 outlook as Florida contract scales |
Latest beats and misses
Who reports nextBeat on EPS
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
- FCNCOFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- FCNCPFY2026 Q3 · October 23, 2026+19.9% EPS+1.0% move
- RDYFY2027 Q2 · October 23, 2026+24.0% EPS-0.2% move
- SLBFY2026 Q3 · October 23, 2026+3.7% EPS+7.1% move
Missed on EPS
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
- HBANMFY2026 Q3 · October 22, 2026-5.3% EPS+0.5% move
Get the SOLV recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-02-13T00:00:14.471520+00:00
- Polygon adjusted daily market bars · 2026-10-25T11:30:42.178724+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-25T11:30:42.175943+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-25. For educational purposes only; not investment advice.